1. Kevric I, Cappel MA, Keeling JH. New world and old world Leishmania infections: a practical review. Dermatol Clin. 2015;33(3):579-93. [
DOI:10.1016/j.det.2015.03.018] [
PMID]
2. Kayani B, Sadiq S, Rashid HB, Ahmed N, Mahmood A, Khaliq MS, et al. Cutaneous Leishmaniasis in Pakistan: a neglected disease needing one health strategy. BMC Infect Dis. 2021;21(1):1-10. [
DOI:10.1186/s12879-021-06327-w] [
PMID] [
PMCID]
3. Seyed N, Taheri T, Vauchy C, Dosset M, Godet Y, Eslamifar A, et al. Immunogenicity evaluation of a rationally designed polytope construct encoding HLA-A* 0201 restricted epitopes derived from Leishmania major related proteins in HLA-A2/DR1 transgenic mice: steps toward polytope vaccine. PLoS One. 2014;9(10): e108848. [
DOI:10.1371/journal.pone.0108848] [
PMID] [
PMCID]
4. Miramin-Mohammadi A, Javadi A, Eskandari SE, Mortazavi H, Rostami MN, Khamesipour A. Immune response in cutaneous leishmaniasis patients with healing vs. non-healing lesions. Iran J Microbiol. 2020;12(3):249-55. [
DOI:10.18502/ijm.v12i3.3243] [
PMID] [
PMCID]
5. Mousavi P, Rahimi Esboei B, Pourhajibagher M, Fakhar M, Shahmoradi Z, Hejazi SH, et al. Anti-leishmanial effects of resveratrol and resveratrol nanoemulsion on Leishmania major. BMC Microbiol. 2022;22(1):1-14. [
DOI:10.1186/s12866-022-02455-8] [
PMID] [
PMCID]
6. Ezra N, Ochoa MT, Craft N. Human immunodeficiency virus and leishmaniasis. J Glob Infect Dis. 2010;2(3):248. [
DOI:10.4103/0974-777X.68528] [
PMID] [
PMCID]
7. Lockard RD, Wilson ME, Rodríguez NE. Sex-Related Differences in Immune Response and Symptomatic Manifestations to Infection with Leishmania Species. J Immunol Res. 2019; 2019:4103819. [
DOI:10.1155/2019/4103819] [
PMID] [
PMCID]
8. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PloS one. 2012; 7(5):e35671. [
DOI:10.1371/journal.pone.0035671] [
PMID] [
PMCID]
9. Global Burden of Disease Study C. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743-800. [
DOI:10.1016/S0140-6736(15)60692-4]
10. Madusanka RK, Silva H, Karunaweera ND. Treatment of Cutaneous Leishmaniasis and Insights into Species-Specific Responses: A Narrative Review. Infect Dis Ther. 2022:1-17. [
DOI:10.1007/s40121-022-00602-2] [
PMID] [
PMCID]
11. Aoun K, Kalboussi Y, Sghaier IB, Souissi O, Hammami H, Bellali H, et al. Assessment of Incubation Period of Cutaneous Leishmaniasis due to Leishmania major in Tunisia. Am J Trop Med Hyg. 2020;103(5):1934-7. [
DOI:10.4269/ajtmh.20-0439] [
PMID] [
PMCID]
12. Alghounaim M, Chivinski J, Barkati S. Cutaneous leishmaniasis in a 12-year-old Syrian immigrant. CMAJ. 2022;194(3):E93-E4. [
DOI:10.1503/cmaj.210847] [
PMID] [
PMCID]
13. Rabienia M, Roudbari Z, Ghanbariasad A, Abdollahi A, Mohammadi E, Mortazavidehkordi N, et al. Exploring membrane proteins of Leishmania major to design a new multiepitope vaccine using immunoinformatics approach. Eur J Pharm Sci. 2020;152:105423. [
DOI:10.1016/j.ejps.2020.105423] [
PMID]
14. Erber AC, Sandler PJ, de Avelar DM, Swoboda I, Cota G, Walochnik J. Diagnosis of visceral and cutaneous leishmaniasis using loop-mediated isothermal amplification (LAMP) protocols: a systematic review and meta-analysis. Parasites Vectors. 2022;15(1):1-16. [
DOI:10.1186/s13071-021-05133-2] [
PMID] [
PMCID]
15. Shams M, Nourmohammadi H, Basati G, Adhami G, Majidiani H, Azizi E. Leishmanolysin gp63: Bioinformatics evidences of immunogenic epitopes in Leishmania major for enhanced vaccine design against zoonotic cutaneous leishmaniasis. Inform Med Unlocked. 2021;24: 100626. [
DOI:10.1016/j.imu.2021.100626]
16. Kedzierski L. Leishmaniasis vaccine: where are we today? J Glob Infect Dis. 2010;2(2):177. [
DOI:10.4103/0974-777X.62881] [
PMID] [
PMCID]
17. Vélez ID, Gilchrist K, Martínez S, Ramírez-Pineda JR, Ashman JA, Alves FP, et al. Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine. 2009;28(2):329-37. [
DOI:10.1016/j.vaccine.2009.10.045] [
PMID]
18. Okwor I, Mou Z, Dong L, UZONNA JE. Protective immunity and vaccination against cutaneous leishmaniasis. Front Immunol. 2012;3:128. [
DOI:10.3389/fimmu.2012.00128] [
PMID] [
PMCID]
19. Adu-Bobie J, Capecchi B, Serruto D, Rappuoli R, Pizza M. Two years into reverse vaccinology. Vaccine. 2003;21(7-8):605-10. [
DOI:10.1016/S0264-410X(02)00566-2]
20. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol. 2002;2(11):845-58. [
DOI:10.1038/nri933] [
PMID]
21. Lakhal-Naouar I, Koles N, Rao M, Morrison EB, Childs JM, Alving CR, et al. Transcutaneous immunization using SLA or rLACK skews the immune response towards a Th1 profile but fails to protect BALB/c mice against a Leishmania major challenge. Vaccine. 2019;37(3):516-23. [
DOI:10.1016/j.vaccine.2018.11.052] [
PMID]
22. Dariushnejad H, Ghorbanzadeh V, Akbari S, Hashemzadeh P. Design of a Novel Recombinant Multi-Epitope Vaccine against Triple-Negative Breast Cancer. Iran Biomed J. 2022;26(2):160-74.
23. Dariushnejad H, Ghorbanzadeh V, Hashemzadeh P. Prediction of B-and T-cell epitopes using in-silico approaches: a solution to the development of recombinant vaccines against covid-19. Minerva Biotechnol Biomol Res. 2021;33(1):36-42. [
DOI:10.23736/S2724-542X.20.02652-X]
24. Chen H-Z, Tang L-L, Yu X-L, Zhou J, Chang Y-F, Wu X. Bioinformatics analysis of epitope-based vaccine design against the novel SARS-CoV-2. Infect Dis Poverty. 2020;9(1):1-10. [
DOI:10.1186/s40249-020-00713-3] [
PMID] [
PMCID]
25. Foroutan M, Ghaffarifar F, Sharifi Z, Dalimi A, Pirestani M. Bioinformatics analysis of ROP8 protein to improve vaccine design against Toxoplasma gondii. Infect Genet Evol. 2018;62: 193-204. [
DOI:10.1016/j.meegid.2018.04.033] [
PMID]
26. Hashemzadeh P, Rouzbahani Ak, Bandehpour M, Kheirandish F, Dariushnejad H, Mohamadi M. Designing a recombinant multiepitope vaccine against Leishmania donovani based immuno-informatics approaches. Minerva Biotecnol. 2020;32(2):52-7. [
DOI:10.23736/S1120-4826.20.02610-5]
27. Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today. 2003;8(20): 934-43. [
DOI:10.1016/S1359-6446(03)02864-2]
28. Liljeroos L, Malito E, Ferlenghi I, Bottomley MJ. Structural and computational biology in the design of immunogenic vaccine antigens. J Immunol Res. 2015;2015. [
DOI:10.1155/2015/156241] [
PMID] [
PMCID]
29. Todolí F, Solano-Gallego L, De Juan R, Morell P, del Carmen Núñez M, Lasa R, et al. Humoral and in vivo cellular immunity against the raw insect-derived recombinant Leishmania infantum antigens KMPII, TRYP, LACK, and papLe22 in dogs from an endemic area. Am J Trop Med Hyg. 2010; 83(6):1287-94. [
DOI:10.4269/ajtmh.2010.09-0784] [
PMID] [
PMCID]
30. Russo D, Turco S, Burns J, Reed S. Stimulation of human T lymphocytes by Leishmania lipopho-sphoglycan-associated proteins. J Immunol. 1992;148(1):202-7.
31. Mortazavidehkordi N, Fallah A, Abdollahi A, Kia V, Khanahmad H, Najafabadi ZG, et al. A lentiviral vaccine expressing KMP11-HASPB fusion protein increases immune response to Leishmania major in BALB/C. Parasitol Res. 2018;117(7):2265-73. [
DOI:10.1007/s00436-018-5915-6] [
PMID]
32. Rodríguez-Cortés A, Ojeda A, López-Fuertes L, Timón M, Altet L, Solano-Gallego L, et al. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge. Vaccine. 2007;25(46):7962-71. [
DOI:10.1016/j.vaccine.2007.08.023] [
PMID]
33. Banuls A-L, Hide M, Prugnolle F. Leishmania and the leishmaniases: a parasite genetic update and advances in taxonomy, epidemiology and pathogenicity in humans. Adv Parasitol. 2007;64: 1-458. [
DOI:10.1016/S0065-308X(06)64001-3]
34. Mottram JC, Coombs GH, Alexander J. Cysteine peptidases as virulence factors of Leishmania. Curr Opin Microbiol. 2004;7(4):375-81. [
DOI:10.1016/j.mib.2004.06.010] [
PMID]
35. He J, Huang F, Li J, Chen Q, Chen D, Chen J. Bioinformatics analysis of four proteins of Leishmania donovani to guide epitopes vaccine design and drug targets selection. Acta tropica. 2019;191:50-9. [
DOI:10.1016/j.actatropica.2018.12.035] [
PMID]
36. Joshi S, Rawat K, Yadav NK, Kumar V, Siddiqi MI, Dube A. Visceral leishmaniasis: advancements in vaccine development via classical and molecular approaches. Front Immunol. 2014;5:380. [
DOI:10.3389/fimmu.2014.00380] [
PMID] [
PMCID]
37. Lee S, Nguyen MT. Recent advances of vaccine adjuvants for infectious diseases. Immune Netw. 2015;15(2):51-7. [
DOI:10.4110/in.2015.15.2.51] [
PMID] [
PMCID]
38. Reed SG, Hsu F-C, Carter D, Orr MT. The science of vaccine adjuvants: advances in TLR4 ligand adjuvants. Curr Opin Immunol. 2016;41:85-90. [
DOI:10.1016/j.coi.2016.06.007] [
PMID]
39. Black M, Trent A, Tirrell M, Olive C. Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists. Expert rev vaccines. 2010;9(2):157-73. [
DOI:10.1586/erv.09.160] [
PMID] [
PMCID]
40. Hashemzadeh P, Ghorbanzadeh V, Valizadeh Otaghsara SM, Dariushnejad H. Novel predicted B-cell epitopes of PSMA for development of prostate cancer vaccine. Int J Pept Res Ther. 2020;26(3):1523-5. [
DOI:10.1007/s10989-019-09954-9]
41. Hashemzadeh P, Ghorbanzadeh V, Lashgarian HE, Kheirandish F, Dariushnejad H. Harnessing Bioinformatic Approaches to Design Novel Multi-epitope Subunit Vaccine Against Leishmania infantum. Int J Pept Res Ther. 2019:1-12. [
DOI:10.1007/s10989-019-09949-6]
42. Dariushnejad H, Ghorbanzadeh V, Akbari S, Hashemzadeh P. Designing a Multiepitope Peptide Vaccine against COVID-19 Variants Utilizing In-silico Tools. Iran J Med Microbiol. 2021;15(5):7. [
DOI:10.30699/ijmm.15.5.592]
43. Pruitt KD, Tatusova T, Maglott DR. NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res. 2007; 35(suppl_1):D61-D5. [
DOI:10.1093/nar/gkl842] [
PMID] [
PMCID]
44. Gasteiger E, Hoogland C, Gattiker A, Wilkins MR, Appel RD, Bairoch A. Protein identification and analysis tools on the ExPASy server. The proteomics protocols handbook: Springer; 2005. p. 571-607. [
DOI:10.1385/1-59259-890-0:571]
45. Magnan CN, Zeller M, Kayala MA, Vigil A, Randall A, Felgner PL, et al. High-throughput prediction of protein antigenicity using protein microarray data. Bioinformatics. 2010;26(23):2936-43. [
DOI:10.1093/bioinformatics/btq551] [
PMID] [
PMCID]
46. Geourjon C, Deleage G. SOPMA: significant improvements in protein secondary structure prediction by consensus prediction from multiple alignments. Bioinformatics. 1995;11(6):681-4. [
DOI:10.1093/bioinformatics/11.6.681] [
PMID]
47. Reche PA, Glutting J-P, Zhang H, Reinherz EL. Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles. Immunogenetics. 2004;56(6):405-19. [
DOI:10.1007/s00251-004-0709-7] [
PMID]
48. Andreatta M, Nielsen M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics. 2016;32(4):511-7. [
DOI:10.1093/bioinformatics/btv639] [
PMID] [
PMCID]
49. Dhanda SK, Mahajan S, Paul S, Yan Z, Kim H, Jespersen MC, et al. IEDB-AR: immune epitope database-analysis resource in 2019. Nucleic Acids Res. 2019;47(W1):W502-W6. [
DOI:10.1093/nar/gkz452] [
PMID] [
PMCID]
50. Chen J, Liu H, Yang J, Chou K-C. Prediction of linear B-cell epitopes using amino acid pair antigenicity scale. Amino acids. 2007;33(3):423-8. [
DOI:10.1007/s00726-006-0485-9] [
PMID]
51. Bhasin M, Raghava GP. Prediction of CTL epitopes using QM, SVM and ANN techniques. Vaccine. 2004;22(23-24):3195-204. [
DOI:10.1016/j.vaccine.2004.02.005] [
PMID]
52. Dhanda SK, Vir P, Raghava GP. Designing of interferon-gamma inducing MHC class-II binders. Biology direct. 2013;8(1):30. [
DOI:10.1186/1745-6150-8-30] [
PMID] [
PMCID]
53. Xia F, Dou Y, Lei G, Tan Y. FPGA accelerator for protein secondary structure prediction based on the GOR algorithm. BMC Bioinform. 2011;12(1): 1-9. [
DOI:10.1186/1471-2105-12-S1-S5] [
PMID] [
PMCID]
54. Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y. The I-TASSER Suite: protein structure and function prediction. Nat Methods. 2015;12(1):7-8. [
DOI:10.1038/nmeth.3213] [
PMID] [
PMCID]
55. Heo L, Park H, Seok C. GalaxyRefine: protein structure refinement driven by side-chain repacking. Nucleic Acids Res. 2013;41(W1): W384-W8. [
DOI:10.1093/nar/gkt458] [
PMID] [
PMCID]
56. Lovell SC, Davis IW, Arendall III WB, De Bakker PI, Word JM, Prisant MG, et al. Structure validation by Cα geometry: ϕ, ψ and Cβ deviation. Proteins: Struct Funct Genet. 2003;50(3):437-50. [
DOI:10.1002/prot.10286] [
PMID]
57. Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 2007;35(suppl_2):W407-W10. [
DOI:10.1093/nar/gkm290] [
PMID] [
PMCID]
58. Colovos C, Yeates TO. Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci. 1993;2(9):1511-9. [
DOI:10.1002/pro.5560020916] [
PMID] [
PMCID]
59. Eisenberg D, Lüthy R, Bowie JU. [20] VERIFY3D: assessment of protein models with three-dimensional profiles. Meth Enzymol. 277: Elsevier; 1997. p. 396-404. [
DOI:10.1016/S0076-6879(97)77022-8]
60. Kim JS, Kim WS, Choi HG, Jang B, Lee K, Park JH, et al. Mycobacterium tuberculosis RpfB drives Th1‐type T cell immunity via a TLR4‐dependent activation of dendritic cells. J Leukoc Biol. 2013;94(4):733-49. [
DOI:10.1189/jlb.0912435] [
PMID]
61. Depledge DP, MacLean LM, Hodgkinson MR, Smith BA, Jackson AP, Ma S, et al. Leishmania-specific surface antigens show sub-genus sequence variation and immune recognition. PLoS Negl Trop Dis. 2010;4(9):e829. [
DOI:10.1371/journal.pntd.0000829] [
PMID] [
PMCID]
62. Reithinger R, Dujardin J-C. Molecular diagnosis of leishmaniasis: current status and future applications. J Clin Microbiol. 2007;45(1):21-5. [
DOI:10.1128/JCM.02029-06] [
PMID] [
PMCID]
63. Zahedifard F, Lee H, No JH, Salimi M, Seyed N, Asoodeh A, et al. Anti-leishmanial activity of Brevinin 2R and its Lauric acid conjugate type against L. major: In vitro mechanism of actions and in vivo treatment potentials. PLoS Negl Trop Dis. 2019;13(2):e0007217. [
DOI:10.1371/journal.pntd.0007217] [
PMID] [
PMCID]
64. Khatoon N, Pandey RK, Prajapati VK. Exploring Leishmania secretory proteins to design B and T cell multiepitope subunit vaccine using immunoinformatics approach. Sci Rep. 2017; 7(1):1-12. [
DOI:10.1038/s41598-017-08842-w] [
PMID] [
PMCID]
65. Moafi M, Rezvan H, Sherkat R, Taleban R. Leishmania vaccines entered in clinical trials: A review of literature. Int J Prev Med. 2019;10. [
DOI:10.4103/ijpvm.IJPVM_116_18] [
PMID] [
PMCID]
66. Das A, Ali N. Combining cationic liposomal delivery with MPL-TDM for cysteine protease cocktail vaccination against Leishmania donovani: evidence for antigen synergy and protection. PLoS Negl Trop Dis. 2014;8(8):e3091. [
DOI:10.1371/journal.pntd.0003091] [
PMID] [
PMCID]
67. Basu R, Bhaumik S, Basu JM, Naskar K, De T, Roy S. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and-resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1-and Th2-like responses in visceral leishmaniasis. J Immunol. 2005;174(11):7160-71. [
DOI:10.4049/jimmunol.174.11.7160] [
PMID]
68. Jain K, Jain N. Vaccines for visceral leishmaniasis: A review. J Immunol Methods. 2015;422:1-12. [
DOI:10.1016/j.jim.2015.03.017] [
PMID]
69. Lari A, Lari N, Biabangard A. Immunoinformatics Approach to Design a Novel Subunit Vaccine Against Visceral Leishmaniasis. Int J Pept Res Ther. 2022;28(1):1-14. [
DOI:10.1007/s10989-021-10344-3] [
PMID] [
PMCID]
70. Khatoon N, Ojha R, Mishra A, Prajapati VK. Examination of antigenic proteins of Trypanosoma cruzi to fabricate an epitope-based subunit vaccine by exploiting epitope mapping mechanism. Vaccine. 2018;36(42):6290-300. [
DOI:10.1016/j.vaccine.2018.09.004] [
PMID]
71. Kalita P, Padhi A, Zhang KY, Tripathi T. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2. Microb Pathog. 2020:104236. [
DOI:10.1016/j.micpath.2020.104236] [
PMID] [
PMCID]
72. Zheng J, Lin X, Wang X, Zheng L, Lan S, Jin S, et al. In silico analysis of epitope-based vaccine candidates against hepatitis B virus polymerase protein. Viruses. 2017;9(5):112. [
DOI:10.3390/v9050112] [
PMID] [
PMCID]
73. Delany I, Rappuoli R, Seib KL. Vaccines, reverse vaccinology, and bacterial pathogenesis. Cold Spring Harb perspect med. 2013;3(5):a012476. [
DOI:10.1101/cshperspect.a012476] [
PMID] [
PMCID]
74. Shahbazi M, Haghkhah M, Rahbar MR, Nezafat N, Ghasemi Y. In silico sub-unit hexavalent peptide vaccine against an Staphylococcus aureus biofilm-related infection. Int J Pept Res Ther. 2016;22(1):101-17. [
DOI:10.1007/s10989-015-9489-1]
75. Scott P, Novais FO. Cutaneous leishmaniasis: immune responses in protection and pathogenesis. Nat Rev Immunol. 2016;16(9):581-92. [
DOI:10.1038/nri.2016.72] [
PMID]
76. Kemp K. Cytokine-producing T cell subsets in human leishmaniasis. Arch Immunol Ther Exp. 2000;48(3):173-6.
77. Modolell M, Choi B-S, Ryan RO, Hancock M, Titus RG, Abebe T, et al. Local suppression of T cell responses by arginase-induced L-arginine depletion in nonhealing leishmaniasis. PLoS Negl Trop Dis. 2009;3(7):e480. [
DOI:10.1371/journal.pntd.0000480] [
PMID] [
PMCID]
78. Dubie T, Mohammed Y. Review on the Role of Host Immune Response in Protection and Immunopathogenesis during Cutaneous Leishmaniasis Infection. J Immunol Res. 2020;2020:2496713. [
DOI:10.1155/2020/2496713] [
PMID] [
PMCID]
79. Aurora R, Creamer TP, Srinivasan R, Rose GD. Local interactions in protein folding: lessons from the α-helix. J Biol Chem. 1997;272(3):1413-6. [
DOI:10.1074/jbc.272.3.1413] [
PMID]
80. Argos P. An investigation of oligopeptides linking domains in protein tertiary structures and possible candidates for general gene fusion. J Mol Biol. 1990;211(4):943-58. [
DOI:10.1016/0022-2836(90)90085-Z]
81. Huang Z, Zhang C, Xing X-H. Design and construction of chimeric linker library with controllable flexibilities for precision protein engineering. Meth Enzymol. 647: Elsevier; 2021. p. 23-49. [
DOI:10.1016/bs.mie.2020.12.004] [
PMID]
82. Rodrigues V, Cordeiro-da-Silva A, Laforge M, Silvestre R, Estaquier J. Regulation of immunity during visceral Leishmania infection. Parasites Vectors. 2016;9(1):118. [
DOI:10.1186/s13071-016-1412-x] [
PMID] [
PMCID]
83. Baghbeheshti S, Hadadian S, Eidi A, Pishkar L, Rahimi H. Effect of flexible and rigid linkers on biological activity of recombinant tetramer variants of S3 antimicrobial peptide. Int J Pept Res Ther. 2021;27(1):457-62. [
DOI:10.1007/s10989-020-10095-7]
84. Bai Y, Ann DK, Shen W-C. Recombinant granulocyte colony-stimulating factor-transferrin fusion protein as an oral myelopoietic agent. Proc Natl Acad Sci U S A. 2005;102(20): 7292-6. [
DOI:10.1073/pnas.0500062102] [
PMID] [
PMCID]
85. Takamatsu N, Watanabe Y, Yanagi H, Meshi T, Shiba T, Okada Y. Production of enkephalin in tobacco protoplasts using tobacco mosaic virus RNA vector. FEBS letters. 1990;269(1):73-6. [
DOI:10.1016/0014-5793(90)81121-4]